<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01933984</url>
  </required_header>
  <id_info>
    <org_study_id>102-CCH-IRP-017</org_study_id>
    <nct_id>NCT01933984</nct_id>
  </id_info>
  <brief_title>Individualized Dosing Schedule of Inhaled Bronchodilator for Endotracheally Intubated COPD Patients</brief_title>
  <official_title>Individualized Dosing Schedule of Inhaled Bronchodilator for Endotracheally Intubated Chronic Obstructive Pulmonary Disease Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shin-hwar Wu</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Changhua Christian Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates whether individualized dosing schedule of inhaled bronchodilator is more
      effective than fixed dosing in reducing airway resistance of intubated COPD patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      *Study Design

        -  This is an open-label, randomized controlled study comparing individualized versus fixed
           bronchodilator dosing schedule for patients with COPD with acute respiratory failure.

           *Patients Enrollment

        -  We will collect 100 patients just admitted to the intensive care unit of Changhua
           Christian Hospital (Changhua, Taiwan) due to COPD with acute respiratory failure.All
           participants will be randomly assigned to either group according to a computer-generated
           allocation sequence in block size of 4 patients.

           *Airway Resistance (Raw) Determination

        -  Enrolled patients will be ventilated by either AVEA (CareFusion, Yorba Linda, CA,
           USA),e500 (Newport Medical Instrument Inc. CA, USA) or Eivta 4 (Drager) ventilator. When
           evaluating Raw, the ventilator settings will be transiently switched to volume control
           mode with fixed tidal volume (500 ml) and constant flow (with a rate of 60 L/min).
           Plateau pressure is measured by manually controlled end-inspiratory pause12. Every
           effort will be exercised to avoid excessive airway secretion or patient agitation during
           measurement. Each measurement will be repeated three times with an interval of at lease
           1 minute and calculate their average. Raw will be calculated by an equation of (peak
           inspiratory pressure - plateau pressure)/flow. After each measurement, the ventilator
           will soon be reverted to its usual settings. Raw will be routinely determined every 8
           hours for 28 days if the ventilator is not discontinued.

           *Technique of Metered Dose Inhaler (MDI) administration through endotracheal tube

        -  The technique basically follows the recommendation of Dhand and Guntur. Airway
           secretions should be sucked out before drug administration. Heat moisture exchanger, but
           not humidifier, is removed. After shaking and warming MDI to hand temperature, the
           canister is connected to an AeroChamber HC MV spacer (Trudell Medical International,
           London, Canada) placed in the inspiratory limb of ventilator circuit 15 cm away from the
           endotracheal tube. Actuation is synchronized with the initiation of inspiration. Each
           actuation is at least 15 second apart.

           *Personal Target Raw Determination

        -  The target Raw of each patient should be determined within 72 hours after their
           admission to intensive care unit. After confirming no inhaled bronchodilator given in
           preceding 2 hours (for fenoterol) or 12 hours (for salmeterol/fluticasone), we will
           deliver 3 consecutive doses of 4 puffs, 8 puffs and 16 puffs of fenoterol MDI (100
           mcg/puff, Berotec;Boehringer Ingelheim, Ingelheim, Germany) inhalation with each dose 15
           minutes apart. The Raw measured 15 minutes later is assigned as this patient's personal
           target Raw.

           *Bronchodilator Delivery Schedule

        -  Each patient will routinely receive 4 puffs of 25 mcg salmeterol /250 mcg fluticasone
           (Seretide Evohaler 250; GlaxoSmithKline Inc. Evreux, France) every 12 hours until the
           discontinuation of ventilator. Each patient will also routinely receive 1 vial of
           Combivent (ipatropium bromide 0.5 mg and salbutamol sulfate 2.5 mg) every 6 hours and be
           injected with intravenous methylprednisolone 40mg every 8 hours in the initial 3
           days.The use of short acting bronchodilator in an as-needed basis is not restricted.
           According to the Raw data determined every 8 hours, individualized dosing group will
           receive an additional 4 puffs of 25 mcg salmeterol /250 mcg fluticasone plus 4 puffs of
           fenoterol if the value is higher than personal target Raw (Once it coincides with
           regular dosing period of salmeterol/fluticasone, only fenoterol will be added). No such
           extra dose will be given to fixed dosing (control) group regardless of Raw value.

           *Statistical Analysis

        -  Student's t test will be used to compare ∆Raw of both groups. For the comparisons of
           other continuous variables without distribution normality, Wilcoxon rank sum test will
           be used. When comparing two categorical variables, Chi-square or Fisher's exact test
           will be used when appropriate. A P value of less than 0.05 is considered significant.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Actual">January 31, 2019</completion_date>
  <primary_completion_date type="Actual">January 31, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>∆Raw (the Difference Between Measured and Target Airway Resistance)</measure>
    <time_frame>Airway resistance will be recorded everyday. If a patient's ventilator was liberated less than 28 days, the day of liberation was the reported time frame. If the day of ventilator liberation was over 28 days, the 28th day was the reported time frame.</time_frame>
    <description>The value can be expressed as relative deviation from target =(measured Raw - target Raw)/target Raw X100</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rapidity of ∆Raw Change</measure>
    <time_frame>Airway resistance will be recorded everyday. If a patient's ventilator was liberated less than 28 days, the day of liberation was the reported time frame. If the day of ventilator liberation was over 28 days, the 28th day was the reported time frame.</time_frame>
    <description>The deviation of ∆Raw from the personal target, which was calculated as (measured Raw−target Raw)/target Raw multiplied by 100.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ventilator-free Days From Day 1 to 28</measure>
    <time_frame>From day 1 to day 28 after enrollment</time_frame>
    <description>Ventilator-free days from day 1 to 28 after enrollment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Participants of Breathing Without Assistance by Day 28</measure>
    <time_frame>the 28th day after enrollment</time_frame>
    <description>The number of participants who breath without ventilator by day 28</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Episode of Nosocomial Pneumonia</measure>
    <time_frame>the 28th day after enrollment</time_frame>
    <description>The number of episodes of nosocomial pneumonia happened by day 28. And nosocomial pneumonia is a lower respiratory infection that was not incubating at the time of hospital admission and that presents clinically 2 or more days after hospitalization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Total Puff of Rescue Short-acting Bronchodilator</measure>
    <time_frame>the 28th day after enrollment</time_frame>
    <description>The number of total puff of rescue short-acting bronchodilator.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Numbers of Episode of Drug-related Adverse Effect</measure>
    <time_frame>From day 1 to day 28 after enrollment</time_frame>
    <description>The numbers of episode of drug-related adverse effect. Naranjo score should be over 4 to be considered drug-related adverse effect. Naranjo score range form 0 to 9, and the higher scores means a higher relationship with drug-related adverse effect.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality Rate</measure>
    <time_frame>the 180th day after enrollment</time_frame>
    <description>The percentage of participants died at day 180.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">51</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>Individualized dosing</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ventilator support
Determining personal target airway resistance
Bronchodilator:Salmeterol/fluticasone 4 puffs inhalation every 12 hours until ventilator discontinuation or the 28th day if ventilator-dependent
Bronchodilator:Ipatropium/salbutamol 1 vial inhalation every 6 hours for the first 3 days
Steroid:Methylprednisolone 40 mg intravenous injection every 8 hours for the first 3 days
Additional broncho-dilators inhalation: Salmeterol/fluticasone (Seretide) 4 puffs plus fenoterol (Berotec) 4 puffs inhalation if personal target airway resistance (measured every 8 hours) not met (until ventilator discontinuation or the 28th day if ventilator-dependent)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fixed dosing</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ventilator support
Determining personal target airway resistance
Bronchodilator:Salmeterol/fluticasone 4 puffs inhalation every 12 hours until ventilator discontinuation or the 28th day if ventilator-dependent
Bronchodilator:Ipatropium/salbutamol 1 vial inhalation every 6 hours for the first 3 days
Steroid:Methylprednisolone 40 mg intravenous injection every 8 hours for the first 3 days
No additional bronchodilator given if personal target airway resistance (measured every 8 hours) not met</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bronchodilators inhalation</intervention_name>
    <description>Salmeterol/fluticasone (Seretide Evohaler) 4 puffs plus fenoterol (Berotec)(0.1mg/puff) 4 puffs inhalation when target airway resistance, measured every 8 hours, not met</description>
    <arm_group_label>Fixed dosing</arm_group_label>
    <arm_group_label>Individualized dosing</arm_group_label>
    <other_name>Salmeterol/fluticasone (Seretide Evohaler)</other_name>
    <other_name>fenoterol (Berotec)(0.1mg/puff)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  chronic obstructive pulmonary disease

          -  acute respiratory failure under ventilator support for less than 72 hours

          -  endotracheal tube inserted

        Exclusion Criteria:

          -  confirmed asthma

          -  Acute Physiology and Chronic Health Evaluation II score over 35

          -  a co-morbidity of septic shock
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shin-hwar Wu</last_name>
    <role>Principal Investigator</role>
    <affiliation>Changhua Christian Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Changhua Christian Hospital</name>
      <address>
        <city>Changhua</city>
        <state>Taiwan</state>
        <zip>50006</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Fuller HD, Dolovich MB, Posmituck G, Pack WW, Newhouse MT. Pressurized aerosol versus jet aerosol delivery to mechanically ventilated patients. Comparison of dose to the lungs. Am Rev Respir Dis. 1990 Feb;141(2):440-4.</citation>
    <PMID>2154154</PMID>
  </reference>
  <reference>
    <citation>Aerosol consensus statement. Consensus Conference on Aerosol Delivery. Chest. 1991 Oct;100(4):1106-9. Review.</citation>
    <PMID>1914568</PMID>
  </reference>
  <reference>
    <citation>Dhand R, Duarte AG, Jubran A, Jenne JW, Fink JB, Fahey PJ, Tobin MJ. Dose-response to bronchodilator delivered by metered-dose inhaler in ventilator-supported patients. Am J Respir Crit Care Med. 1996 Aug;154(2 Pt 1):388-93.</citation>
    <PMID>8756811</PMID>
  </reference>
  <reference>
    <citation>Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, Janecek E, Domecq C, Greenblatt DJ. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981 Aug;30(2):239-45.</citation>
    <PMID>7249508</PMID>
  </reference>
  <reference>
    <citation>Malliotakis P, Linardakis M, Gavriilidis G, Georgopoulos D. Duration of salmeterol-induced bronchodilation in mechanically ventilated chronic obstructive pulmonary disease patients: a prospective clinical study. Crit Care. 2008;12(6):R140. doi: 10.1186/cc7117. Epub 2008 Nov 14.</citation>
    <PMID>19014570</PMID>
  </reference>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>August 29, 2013</study_first_submitted>
  <study_first_submitted_qc>August 29, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 4, 2013</study_first_posted>
  <results_first_submitted>February 24, 2019</results_first_submitted>
  <results_first_submitted_qc>February 10, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">February 21, 2020</results_first_posted>
  <last_update_submitted>July 8, 2020</last_update_submitted>
  <last_update_submitted_qc>July 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Changhua Christian Hospital</investigator_affiliation>
    <investigator_full_name>Shin-hwar Wu</investigator_full_name>
    <investigator_title>Attending physician</investigator_title>
  </responsible_party>
  <keyword>Bronchodilator agents,</keyword>
  <keyword>chronic obstructive pulmonary disease,</keyword>
  <keyword>endotracheal intubation,</keyword>
  <keyword>mechanical ventilator</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluticasone</mesh_term>
    <mesh_term>Fenoterol</mesh_term>
    <mesh_term>Salmeterol Xinafoate</mesh_term>
    <mesh_term>Bronchodilator Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>We have no plan to share IPD.</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 24, 2013</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/84/NCT01933984/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Individualized Dosing</title>
          <description>Ventilator support
Determining personal target airway resistance
Salmeterol/fluticasone 4 puffs inhalation q12h until ventilator discontinuation or the 28th day if ventilator-dependent
Ipatropium/salbutamol 1 vial inhalation q6h for the first 3 days
Methylprednisolone 40 mg intravenous injection q8h for the first 3 days
Additional Salmeterol/fluticasone (Seretide) 4 puffs plus fenoterol (Berotec) 4 puffs inhalation if personal target airway resistance (measured every 8 hours) not met</description>
        </group>
        <group group_id="P2">
          <title>Fixed Dosing</title>
          <description>Ventilator support
Determining personal target airway resistance
Salmeterol/fluticasone 4 puffs inhalation q12h until ventilator discontinuation or the 28th day if ventilator-dependent
Ipatropium/salbutamol 1 vial inhalation q6h for the first 3 days
Methylprednisolone 40 mg intravenous injection q8h for the first 3 days
No additional bronchodilator given if personal target airway resistance (measured every 8 hours) not met</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Individualized Dosing</title>
          <description>Ventilator support
Determining personal target airway resistance
Bronchodilator:Salmeterol/fluticasone 4 puffs inhalation every 12 hours until ventilator discontinuation or the 28th day if ventilator-dependent
Bronchodilator:Ipatropium/salbutamol 1 vial inhalation every 6 hours for the first 3 days
Steroid:Methylprednisolone 40 mg intravenous injection every 8 hours for the first 3 days
Additional broncho-dilators inhalation: Salmeterol/fluticasone (Seretide) 4 puffs plus fenoterol (Berotec) 4 puffs inhalation if personal target airway resistance (measured every 8 hours) not met (until ventilator discontinuation or the 28th day if ventilator-dependent)</description>
        </group>
        <group group_id="B2">
          <title>Fixed Dosing</title>
          <description>Ventilator support
Determining personal target airway resistance
Bronchodilator:Salmeterol/fluticasone 4 puffs inhalation every 12 hours until ventilator discontinuation or the 28th day if ventilator-dependent
Bronchodilator:Ipatropium/salbutamol 1 vial inhalation every 6 hours for the first 3 days
Steroid:Methylprednisolone 40 mg intravenous injection every 8 hours for the first 3 days
No additional bronchodilator given if personal target airway resistance (measured every 8 hours) not met</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="26"/>
            <count group_id="B2" value="25"/>
            <count group_id="B3" value="51"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="73.6" spread="13.3"/>
                    <measurement group_id="B2" value="77.9" spread="8.7"/>
                    <measurement group_id="B3" value="75.7" spread="11.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25.6" spread="11.6"/>
                    <measurement group_id="B2" value="23.4" spread="4.9"/>
                    <measurement group_id="B3" value="24.5" spread="8.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>∆Raw (the Difference Between Measured and Target Airway Resistance)</title>
        <description>The value can be expressed as relative deviation from target =(measured Raw - target Raw)/target Raw X100</description>
        <time_frame>Airway resistance will be recorded everyday. If a patient's ventilator was liberated less than 28 days, the day of liberation was the reported time frame. If the day of ventilator liberation was over 28 days, the 28th day was the reported time frame.</time_frame>
        <population>The deviation of Raw from the personal target, which was calculated as (measured Raw−target Raw)/target Raw.</population>
        <group_list>
          <group group_id="O1">
            <title>Individualized Dosing</title>
            <description>Ventilator support
Determining personal target airway resistance
Bronchodilator:Salmeterol/fluticasone 4 puffs inhalation every 12 hours until ventilator discontinuation or the 28th day if ventilator-dependent
Bronchodilator:Ipatropium/salbutamol 1 vial inhalation every 6 hours for the first 3 days
Steroid:Methylprednisolone 40 mg intravenous injection every 8 hours for the first 3 days
Additional broncho-dilators inhalation: Salmeterol/fluticasone (Seretide) 4 puffs plus fenoterol (Berotec) 4 puffs inhalation if personal target airway resistance (measured every 8 hours) not met (until ventilator discontinuation or the 28th day if ventilator-dependent) salmeterol/fluticasone: Each puff contains 25 mcg salmeterol /250 mcg fluticasone ipatropium/salbutamol: Each vial contains ipatropium bromide 0.5 mg and salbutamol sulfate 2.5 mg Methylprednisolone Additional broncho-dilators inhalation: Salmeterol/fluticasone (Seretide Evohaler) 4 puffs plus fenoterol (Berotec)(0</description>
          </group>
          <group group_id="O2">
            <title>Fixed Dosing</title>
            <description>Ventilator support
Determining personal target airway resistance
Bronchodilator:Salmeterol/fluticasone 4 puffs inhalation every 12 hours until ventilator discontinuation or the 28th day if ventilator-dependent
Bronchodilator:Ipatropium/salbutamol 1 vial inhalation every 6 hours for the first 3 days
Steroid:Methylprednisolone 40 mg intravenous injection every 8 hours for the first 3 days
No additional bronchodilator given if personal target airway resistance (measured every 8 hours) not met salmeterol/fluticasone: Each puff contains 25 mcg salmeterol /250 mcg fluticasone ipatropium/salbutamol: Each vial contains ipatropium bromide 0.5 mg and salbutamol sulfate 2.5 mg Methylprednisolone Determining personal target airway resistance: Three consecutive doses of 4, 8 and 16 puffs of fenoterol MDI (100 mcg/puff, Berotec;Boehringer Ingelheim, Ingelheim, Germany) inhalation with each dose 15 minutes apart. The airway resistance measured 15 minutes later is assigned as th</description>
          </group>
        </group_list>
        <measure>
          <title>∆Raw (the Difference Between Measured and Target Airway Resistance)</title>
          <description>The value can be expressed as relative deviation from target =(measured Raw - target Raw)/target Raw X100</description>
          <population>The deviation of Raw from the personal target, which was calculated as (measured Raw−target Raw)/target Raw.</population>
          <units>percentage of relative Raw deviation</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9" spread="10"/>
                    <measurement group_id="O2" value="44" spread="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Rapidity of ∆Raw Change</title>
        <description>The deviation of ∆Raw from the personal target, which was calculated as (measured Raw−target Raw)/target Raw multiplied by 100.</description>
        <time_frame>Airway resistance will be recorded everyday. If a patient's ventilator was liberated less than 28 days, the day of liberation was the reported time frame. If the day of ventilator liberation was over 28 days, the 28th day was the reported time frame.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Individualized Dosing</title>
            <description>Ventilator support
Determining personal target airway resistance
Bronchodilator:Salmeterol/fluticasone 4 puffs inhalation every 12 hours until ventilator discontinuation or the 28th day if ventilator-dependent
Bronchodilator:Ipatropium/salbutamol 1 vial inhalation every 6 hours for the first 3 days
Steroid:Methylprednisolone 40 mg intravenous injection every 8 hours for the first 3 days
Additional broncho-dilators inhalation: Salmeterol/fluticasone (Seretide) 4 puffs plus fenoterol (Berotec) 4 puffs inhalation if personal target airway resistance (measured every 8 hours) not met (until ventilator discontinuation or the 28th day if ventilator-dependent)</description>
          </group>
          <group group_id="O2">
            <title>Fixed Dosing</title>
            <description>Ventilator support
Determining personal target airway resistance
Bronchodilator:Salmeterol/fluticasone 4 puffs inhalation every 12 hours until ventilator discontinuation or the 28th day if ventilator-dependent
Bronchodilator:Ipatropium/salbutamol 1 vial inhalation every 6 hours for the first 3 days
Steroid:Methylprednisolone 40 mg intravenous injection every 8 hours for the first 3 days
No additional bronchodilator given if personal target airway resistance (measured every 8 hours) not met</description>
          </group>
        </group_list>
        <measure>
          <title>Rapidity of ∆Raw Change</title>
          <description>The deviation of ∆Raw from the personal target, which was calculated as (measured Raw−target Raw)/target Raw multiplied by 100.</description>
          <units>percentage of relative Raw deviation</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3" spread="9.7"/>
                    <measurement group_id="O2" value="0.4" spread="13.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ventilator-free Days From Day 1 to 28</title>
        <description>Ventilator-free days from day 1 to 28 after enrollment</description>
        <time_frame>From day 1 to day 28 after enrollment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Individualized Dosing</title>
            <description>Ventilator support
Determining personal target airway resistance
Salmeterol/fluticasone 4 puffs inhalation q12h until ventilator discontinuation or the 28th day if ventilator-dependent
Ipatropium/salbutamol 1 vial inhalation q6h for the first 3 days
Methylprednisolone 40 mg intravenous injection q8h for the first 3 days
Additional Salmeterol/fluticasone (Seretide) 4 puffs plus fenoterol (Berotec) 4 puffs inhalation if personal target airway resistance (measured every 8 hours) not met</description>
          </group>
          <group group_id="O2">
            <title>Fixed Dosing</title>
            <description>Ventilator support
Determining personal target airway resistance
Salmeterol/fluticasone 4 puffs inhalation q12h until ventilator discontinuation or the 28th day if ventilator-dependent
Ipatropium/salbutamol 1 vial inhalation q6h for the first 3 days
Methylprednisolone 40 mg intravenous injection q8h for the first 3 days
No additional bronchodilator given if personal target airway resistance (measured every 8 hours) not met</description>
          </group>
        </group_list>
        <measure>
          <title>Ventilator-free Days From Day 1 to 28</title>
          <description>Ventilator-free days from day 1 to 28 after enrollment</description>
          <units>day</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Participants of Breathing Without Assistance by Day 28</title>
        <description>The number of participants who breath without ventilator by day 28</description>
        <time_frame>the 28th day after enrollment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Individualized Dosing</title>
            <description>Ventilator support
Determining personal target airway resistance
Salmeterol/fluticasone 4 puffs inhalation q12h until ventilator discontinuation or the 28th day if ventilator-dependent
Ipatropium/salbutamol 1 vial inhalation q6h for the first 3 days
Methylprednisolone 40 mg intravenous injection q8h for the first 3 days
Additional Salmeterol/fluticasone (Seretide) 4 puffs plus fenoterol (Berotec) 4 puffs inhalation if personal target airway resistance (measured every 8 hours) not met</description>
          </group>
          <group group_id="O2">
            <title>Fixed Dosing</title>
            <description>Ventilator support
Determining personal target airway resistance
Salmeterol/fluticasone 4 puffs inhalation q12h until ventilator discontinuation or the 28th day if ventilator-dependent
Ipatropium/salbutamol 1 vial inhalation q6h for the first 3 days
Methylprednisolone 40 mg intravenous injection q8h for the first 3 days
No additional bronchodilator given if personal target airway resistance (measured every 8 hours) not met</description>
          </group>
        </group_list>
        <measure>
          <title>The Participants of Breathing Without Assistance by Day 28</title>
          <description>The number of participants who breath without ventilator by day 28</description>
          <units>the number of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Episode of Nosocomial Pneumonia</title>
        <description>The number of episodes of nosocomial pneumonia happened by day 28. And nosocomial pneumonia is a lower respiratory infection that was not incubating at the time of hospital admission and that presents clinically 2 or more days after hospitalization.</description>
        <time_frame>the 28th day after enrollment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Individualized Dosing</title>
            <description>Ventilator support
Determining personal target airway resistance
Salmeterol/fluticasone 4 puffs inhalation q12h until ventilator discontinuation or the 28th day if ventilator-dependent
Ipatropium/salbutamol 1 vial inhalation q6h for the first 3 days
Methylprednisolone 40 mg intravenous injection q8h for the first 3 days
Additional Salmeterol/fluticasone (Seretide) 4 puffs plus fenoterol (Berotec) 4 puffs inhalation if personal target airway resistance (measured every 8 hours) not met</description>
          </group>
          <group group_id="O2">
            <title>Fixed Dosing</title>
            <description>Ventilator support
Determining personal target airway resistance
Salmeterol/fluticasone 4 puffs inhalation q12h until ventilator discontinuation or the 28th day if ventilator-dependent
Ipatropium/salbutamol 1 vial inhalation q6h for the first 3 days
Methylprednisolone 40 mg intravenous injection q8h for the first 3 days
No additional bronchodilator given if personal target airway resistance (measured every 8 hours) not met</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Episode of Nosocomial Pneumonia</title>
          <description>The number of episodes of nosocomial pneumonia happened by day 28. And nosocomial pneumonia is a lower respiratory infection that was not incubating at the time of hospital admission and that presents clinically 2 or more days after hospitalization.</description>
          <units>episodes of nosocomial pneumonia</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Total Puff of Rescue Short-acting Bronchodilator</title>
        <description>The number of total puff of rescue short-acting bronchodilator.</description>
        <time_frame>the 28th day after enrollment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Individualized Dosing</title>
            <description>Ventilator support
Determining personal target airway resistance
Salmeterol/fluticasone 4 puffs inhalation q12h until ventilator discontinuation or the 28th day if ventilator-dependent
Ipatropium/salbutamol 1 vial inhalation q6h for the first 3 days
Methylprednisolone 40 mg intravenous injection q8h for the first 3 days
Additional Salmeterol/fluticasone (Seretide) 4 puffs plus fenoterol (Berotec) 4 puffs inhalation if personal target airway resistance (measured every 8 hours) not met</description>
          </group>
          <group group_id="O2">
            <title>Fixed Dosing</title>
            <description>Ventilator support
Determining personal target airway resistance
Salmeterol/fluticasone 4 puffs inhalation q12h until ventilator discontinuation or the 28th day if ventilator-dependent
Ipatropium/salbutamol 1 vial inhalation q6h for the first 3 days
Methylprednisolone 40 mg intravenous injection q8h for the first 3 days
No additional bronchodilator given if personal target airway resistance (measured every 8 hours) not met</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Total Puff of Rescue Short-acting Bronchodilator</title>
          <description>The number of total puff of rescue short-acting bronchodilator.</description>
          <units>puffs</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Numbers of Episode of Drug-related Adverse Effect</title>
        <description>The numbers of episode of drug-related adverse effect. Naranjo score should be over 4 to be considered drug-related adverse effect. Naranjo score range form 0 to 9, and the higher scores means a higher relationship with drug-related adverse effect.</description>
        <time_frame>From day 1 to day 28 after enrollment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Individualized Dosing</title>
            <description>Ventilator support
Determining personal target airway resistance
Salmeterol/fluticasone 4 puffs inhalation q12h until ventilator discontinuation or the 28th day if ventilator-dependent
Ipatropium/salbutamol 1 vial inhalation q6h for the first 3 days
Methylprednisolone 40 mg intravenous injection q8h for the first 3 days
Additional Salmeterol/fluticasone (Seretide) 4 puffs plus fenoterol (Berotec) 4 puffs inhalation if personal target airway resistance (measured every 8 hours) not met</description>
          </group>
          <group group_id="O2">
            <title>Fixed Dosing</title>
            <description>Ventilator support
Determining personal target airway resistance
Salmeterol/fluticasone 4 puffs inhalation q12h until ventilator discontinuation or the 28th day if ventilator-dependent
Ipatropium/salbutamol 1 vial inhalation q6h for the first 3 days
Methylprednisolone 40 mg intravenous injection q8h for the first 3 days
No additional bronchodilator given if personal target airway resistance (measured every 8 hours) not met</description>
          </group>
        </group_list>
        <measure>
          <title>Numbers of Episode of Drug-related Adverse Effect</title>
          <description>The numbers of episode of drug-related adverse effect. Naranjo score should be over 4 to be considered drug-related adverse effect. Naranjo score range form 0 to 9, and the higher scores means a higher relationship with drug-related adverse effect.</description>
          <units>episodes</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mortality Rate</title>
        <description>The percentage of participants died at day 180.</description>
        <time_frame>the 180th day after enrollment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Individualized Dosing</title>
            <description>Ventilator support
Determining personal target airway resistance
Salmeterol/fluticasone 4 puffs inhalation q12h until ventilator discontinuation or the 28th day if ventilator-dependent
Ipatropium/salbutamol 1 vial inhalation q6h for the first 3 days
Methylprednisolone 40 mg intravenous injection q8h for the first 3 days
Additional Salmeterol/fluticasone (Seretide) 4 puffs plus fenoterol (Berotec) 4 puffs inhalation if personal target airway resistance (measured every 8 hours) not met</description>
          </group>
          <group group_id="O2">
            <title>Fixed Dosing</title>
            <description>Ventilator support
Determining personal target airway resistance
Salmeterol/fluticasone 4 puffs inhalation q12h until ventilator discontinuation or the 28th day if ventilator-dependent
Ipatropium/salbutamol 1 vial inhalation q6h for the first 3 days
Methylprednisolone 40 mg intravenous injection q8h for the first 3 days
No additional bronchodilator given if personal target airway resistance (measured every 8 hours) not met</description>
          </group>
        </group_list>
        <measure>
          <title>Mortality Rate</title>
          <description>The percentage of participants died at day 180.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From day 1 to day 28</time_frame>
      <desc>The definition of adverse event and/or serious adverse event, used to collect adverse event information, are same with the clinicaltrials.gov definitions. However, only events with Naranjo score over 4 were be considered as drug-related.
No treatment-related adverse events could be found in this study. So, no additional information could be offered.</desc>
      <group_list>
        <group group_id="E1">
          <title>Individualized Dosing</title>
          <description>Ventilator support
Determining personal target airway resistance
Bronchodilator:Salmeterol/fluticasone 4 puffs inhalation every 12 hours until ventilator discontinuation or the 28th day if ventilator-dependent
Bronchodilator:Ipatropium/salbutamol 1 vial inhalation every 6 hours for the first 3 days
Steroid:Methylprednisolone 40 mg intravenous injection every 8 hours for the first 3 days
Additional broncho-dilators inhalation: Salmeterol/fluticasone (Seretide) 4 puffs plus fenoterol (Berotec) 4 puffs inhalation if personal target airway resistance (measured every 8 hours) not met (until ventilator discontinuation or the 28th day if ventilator-dependent) salmeterol/fluticasone: Each puff contains 25 mcg salmeterol /250 mcg fluticasone ipatropium/salbutamol: Each vial contains ipatropium bromide 0.5 mg and salbutamol sulfate 2.5 mg Methylprednisolone Additional broncho-dilators inhalation: Salmeterol/fluticasone (Seretide Evohaler) 4 puffs plus fenoterol (Berotec)(0</description>
        </group>
        <group group_id="E2">
          <title>Fixed Dosing</title>
          <description>Ventilator support
Determining personal target airway resistance
Bronchodilator:Salmeterol/fluticasone 4 puffs inhalation every 12 hours until ventilator discontinuation or the 28th day if ventilator-dependent
Bronchodilator:Ipatropium/salbutamol 1 vial inhalation every 6 hours for the first 3 days
Steroid:Methylprednisolone 40 mg intravenous injection every 8 hours for the first 3 days
No additional bronchodilator given if personal target airway resistance (measured every 8 hours) not met salmeterol/fluticasone: Each puff contains 25 mcg salmeterol /250 mcg fluticasone ipatropium/salbutamol: Each vial contains ipatropium bromide 0.5 mg and salbutamol sulfate 2.5 mg Methylprednisolone Determining personal target airway resistance: Three consecutive doses of 4, 8 and 16 puffs of fenoterol MDI (100 mcg/puff, Berotec;Boehringer Ingelheim, Ingelheim, Germany) inhalation with each dose 15 minutes apart. The airway resistance measured 15 minutes later is assigned as th</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Shin-Hwar Wu</name_or_title>
      <organization>Division of Critical Care Medicine, Department of Medicine, Changhua Christian Hospital</organization>
      <phone>886-4-7238595 ext 3971</phone>
      <email>126366@cch.org.tw</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

